Shanghai Fudan Zhangjiang Biopharmaceutical develops, manufactures and markets innovative pharmaceuticals for unmet medical needs.
Founded in 1996 and headquartered in Shanghai, China, Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. focuses on innovative therapeutics, particularly in oncology and autoimmune disorders, with a primary focus on China and plans to expand into Europe and North America. In 2021 it generated revenue of USD 176.75 mn and EBITDA of USD 42.03 mn. It has completed 3 deals, including a USD 4.40 mn PIPE round with New Enterprise Capital as the investor, and the directory lists its stage as Series B.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.? This is my company